5:28 PM
 | 
May 03, 2010
 |  BC Extra  |  Company News

FDA reviewing safety of GnRH agonists

FDA is reviewing the safety of gonadotropin-releasing hormone (GnRH) agonists after data from published studies showed an increased risk of diabetes and cardiovascular disease, including heart attack, sudden cardiac death and stroke, in men receiving androgen deprivation...

Read the full 161 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >